Product Program year 2020 Source: CMS Open Payments

Vanatab DM

Drug Cough and Cold

NDC 58809-198-60

Open in the dashboard

General payments

$690

4 payments

Research payments

0 payments

Through program year 2020, $690 in general payments and $0 in research payments were reported against Vanatab DM (Cough and Cold).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row

Year	Kind	Amount	Payments
2020	General	$690	4

Breakdown

Who paid General payments · program year 2020

GM Pharmaceuticals, Inc. $690 4 payments

Top recipients General payments · program year 2020

Livania Zavala-Spinetti Pediatrics · Edinburg, TX $407 59% · 2 payments
Syed Yusoof Internal Medicine · El Paso, TX $143 21% · 1 payment
Gilberto Gomez Pediatrics · El Paso, TX $140 20% · 1 payment

Each share is of general payments naming this product in 2020.

Specialties paid General payments · program year 2020

Pediatrics $547 79% · 2 practitioners
Internal Medicine $143 21% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020

Texas $690 100% · 3 recipients

Each share is of general payments naming this product in 2020 where a state was reported.

Records

4 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.